Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today again confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms. KALY’s proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions.
| DALLAS, March 2, 2020 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today again confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms. KALY’s proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s U.S. Patented Cannabis Extraction Process. As detailed in a recently published research study (Journal of Cannabis Research) the KALY U.S. Patented CBD extract provides significant anti-inflammatory responses in vitro. The next phase of research is now moving forward in preclinical in vivo research to expand evaluation of the effects on lung function, total body distribution, whole body clearance of the extract and dosage evaluations for maximal efficacy. KALY has filed a new patent application specifically on its CBD formulation for symptoms associated with COPD and other similar respiratory conditions. KALY has also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions that result from respiratory inflammation. To learn more about RespRx, visit https://www.resprx.com/ Follow further developments at https://www.kali-extracts.com/ This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors. CONTACT:
SOURCE Kali-Extracts, Inc. | ||
Company Codes: OTC-PINK:KALY, OtherOTC:KALY |
View original content:
